Exelixis Inc. Reports Strong Financial Performance for 2025

In 2025, Exelixis reported net product revenues of $2.12 billion, marking a significant increase from $1.81 billion in 2024. This growth is largely attributed to a 16% rise in units sold for its flagship product, CABOMETYX® (cabozantinib), which has seen heightened demand, particularly for its use in combination therapies for advanced renal cell carcinoma (RCC). Total revenues reached $2.32 billion, up from $2.17 billion in the previous year.

The company’s net income saw a remarkable increase from $521 million in 2024 to $783 million in 2025, reflecting effective cost management and strong sales performance.

Exelixis's revenue performance varied significantly across global markets in 2025. The U.S. market remained the strongest performer, generating approximately $2.14 billion, a 17.41% increase compared to $1.82 billion in 2024. However, revenues from Europe plummeted by 51.62% to $154.1 million, while Japan saw a decline of 5.49% to $25.59 million.

A breakdown of Exelixis’s revenues by product reveals that gross product revenues were $3.01 billion, reflecting a 19.6% growth from $2.51 billion in 2024. However, collaboration service revenues decreased by 45.08% to $197.3 million, highlighting some challenges in partnership-driven revenue streams.

Exelixis remains focused on expanding its oncology pipeline, which includes promising candidates such as zanzalintinib, an oral kinase inhibitor currently undergoing pivotal trials for various cancers including colorectal cancer and neuroendocrine tumors. The company has initiated several large-scale clinical trials, such as STELLAR-001 and STELLAR-002, with positive preliminary results reported at major oncology conferences.

Despite its growth trajectory, Exelixis faces significant regulatory and market challenges. The introduction of the Inflation Reduction Act has altered the landscape for drug pricing and reimbursement in the U.S., impacting Exelixis’s pricing strategies. Nevertheless, the company qualifies for the small biotech exception under the Act, providing a temporary buffer against price negotiations until 2028.

Exelixis's balance sheet reflects a solid financial position with total assets amounting to $2.84 billion in 2025, down from $2.94 billion in 2024. Total liabilities decreased to $683.1 million, while total equity stood at $2.16 billion.

The cash flow statement indicates a net change in cash of $265.1 million, with robust cash generation from operating activities at $884.2 million. However, cash outflows related to financing activities were significant, totaling $969.5 million, largely due to share repurchases.

In a strategic move to bolster its research and development initiatives, Exelixis appointed Dana T. Aftab, Ph.D., as the new Executive Vice President of Research and Development in August 2025. This leadership change is expected to enhance the company's focus on innovative drug development and strengthen its competitive edge in the oncology market.

Looking ahead, Exelixis is poised for continued growth as it expands its oncology product pipeline through ongoing research and strategic collaborations. The company anticipates advancing additional development candidates into preclinical phases in 2026 and beyond, aiming to deliver impactful therapies to patients suffering from cancer.

In conclusion, Exelixis Inc. has demonstrated resilience and growth in 2025, navigating through regulatory challenges while maintaining a robust revenue stream driven by its flagship oncology products. With a focus on innovation and strategic partnerships, the company is well-positioned to make significant strides in cancer treatment in the coming years.